admin

June 9, 2022

June 9, 2022

CureLab Veterinary Launches Equity Crowdfunding Campaign on Wefunder to Revolutionize Medicine for Dogs, Cats, and Horses

CureLab Veterinary addresses a $207 billion global pet cancer market, and Elenavet™, the company’s lead drug, has successfully treated 10 out of 11 dogs with breast cancer; this is an equity crowdfunding opportunity for early equity investment where one can own part of a promising biotech company
May 19, 2022

May 19, 2022

Review Paper Published by CureLab Veterinary and University of Camerino Shows Additional Opportunities for Use of Elenavet in Treating Domestic Animals

CureLab Veterinary is preparing to start the USDA-CVB process with its patented product and is raising funds to complete the USDA-CVB licensing process in the United States
May 12, 2022

May 12, 2022

CureLab Veterinary’s DNA Plasmid, Elenavet, Designated a Biologic Veterinary Product by the European Medicines Agency

CureLab Veterinary plans to obtain regulatory approval in Europe, a market with significant revenue potential
May 6, 2022

May 6, 2022

CureLab Veterinary Secures Patent Protection for P62 Plasmid Therapeutic in South Korea

Patent registration in South Korea enables CureLab Veterinary to pursue a market with high commercial potential